Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Head and Neck
Conditions
Keywords
Head and Neck Cancer
Brief summary
This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans make detailed, computerized pictures of areas inside the body where the drug is used. Giving panitumumab-IRDye800 and 89Zr-panitumumab to patients with head and neck cancer may help doctors find metastatic lymph nodes better than current methods \[positron emission tomography (PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations\].
Detailed description
For patients with head and neck cancer, detection of malignant cells within nearby lymph nodes (LNs) is an important measure of the extent and severity of the cancer. LNs are a key immunologic organ involved in overall immune surveillance. Historically, LN or LNs were harvested before the surgery of curative intent, evaluated pathologically, and then tumor status of the harvested LNs were utilized to inform the individual surgical plan. These LNs became known as sentinel lymph nodes. In recent years, techniques have been developed to utilize peritumoral injection (around the tumor) of tumor labels that could identify tumor in the LNs without biopsy, ie, only LNs that were tumor-positive would be removed. However, in some patients, this technique could be limited by the location of the primary cancer. Effective and sensitive systemically-administered labels would be a significant advancement. The systemically-administered label 18F-fluorodeoxyglucose (18F-FDG), detected by positron emission tomography / computed tomography (PET/CT) and/or PET / magnetic imaging resonance (PET/MRI) radiologic scans and representing current regular medical care, has provided improvement in detection of cancer-positive LNs. However, further enhancements may be possible. Participants with squamous cell carcinoma of the head and neck (SCCHN) and scheduled to undergo regular medical care surgery with curative intent, were assigned to 2 study groups on the basis of whether regular medical care scans using 18F-FDG PET/CT or PET/MRI had indicated that cancer was suspected in the lymph nodes (LN+ or cN+), or without suspected cancer in the lymph nodes (LN- or cN0). Following the 18F-FDG, and prior to surgery, 89Zr-panitumumab was systemically administered by intravenous infusion, and a PET-CT imaging scan was conducted. Research imaging will be performed intraoperatively using optical imaging devices and a high-energy gamma probe. Subsequently, the excised tissue will evaluated ex vivo (back table) using radioactive (89Zr-panitumumab) and fluorescence (panitumumab-IRDye800) imaging techniques. Regular medical care surgical excision of the tumor and adjacent LN was conducted on Day 2 to 5. After surgery, patients are followed up at 15 and 30 days. PRIMARY OBJECTIVES: I. Determine the sensitivity and specificity of zirconium(89Zr)-panitumumab (89Zr-panitumumab) for the detection of tumor-involved regional lymph nodes. SECONDARY OBJECTIVES: I. Determine the number (proportion) of lymph nodes determined to be tumor positive by histological and/or pathological evaluation that were NOT predicted tumor-positive by 89Zr-panitumumab labeling. EXPLORATORY OBJECTIVES: I. Determine the sensitivity and specificity of panitumumab-IRDye800 for the detection of tumor-involved regional lymph nodes. II. Determine the number (proportion) of lymph nodes determined to be tumor positive by histological and/or pathological evaluation that were NOT predicted tumor-positive by panitumumab-IRDye800 labeling.
Interventions
30 mg administered intravenously (IV)
DRUG89-Zirconium (Zr-89) Panitumumab
0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
DEVICEPinpoint IR IR9000 fluorescence imaging system (FIS)
Handheld fluorescence-imaging endoscope manufactured by Novadaq
DEVICESPY-PHI IR9000 fluorescence imaging system (FIS)
Handheld fluorescence-imaging endoscope manufactured by Novadaq
DEVICEExplorer Air camera
Fluorescence camera manufactured by SurgVision
DEVICEPDE-NEO II camera
Medical infrared camera manufactured by Hamamatsu Photonics KK
DEVICEFIS-00 fluorescence imaging system (FIS)
Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
DEVICEDa Vinci Firefly Imaging System
Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
DEVICEIGP-ELVIS-v4 Macroscopic Specimen Imager
Macroscopic specimen imager manufactured by LI-COR Biosciences
DEVICEVevo 3100 LAZR-X
Photoacoustic ultrasound imaging system manufactured by VisualSonics
DEVICEPearl Triology Imaging System
Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
DEVICEOdyssey CLx Imaging System
Infrared fluorescent-imaging system manufactured by LI-COR Biosciences
DEVICELeica fluorescence microscope
Fluorescence microscope manufactured by Leica
Sponsors
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Andrei Iagaru
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck. * Subjects diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Subjects with recurrent disease or a new primary will be allowed. * Planned standard of care surgery with curative intent for squamous cell carcinoma. * Hemoglobin ≥ 9 gm/dL. * White blood cell count \> 3000/mm³. * Platelet count ≥ 100,000/mm³. * Serum creatinine ≤ 1.5 times upper reference range.
Exclusion criteria
* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment. * Previous bilateral neck dissection. * History of infusion reactions to monoclonal antibody therapies. * Pregnant or breastfeeding. * Magnesium or potassium lower than the normal institutional values. * Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. * Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis. * Severe renal disease or anuria. * Known hypersensitivity to deferoxamine or any of its components.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | up to 5 days | The ability of 89Zr-panitumumab and 18F-fluorodeoxyglucose (18F-FDG) to detect tumor in lymph nodes were assessed on the basis of radiologic scans and histopathologic evaluation of excised lymph nodes (LNs). The histopathologic assessment was considered the definitive, regular medical care, assessment. The outcome is reported by study group as the number of LNs that were identified as tumor-positive by 18F-FDG- and 89Zr-panitumumab, stratified by the tumor-positivity as assessed by histopathology, and expressed as the number of LNs that were tumor-positive by both, negative for both, or positive for one and not the other. Results are also provided by study group for the number of LNs that tumor-positive by both 18F-FDG- and 89Zr-panitumumab, negative for both, or positive for one and not the other. The outcome is numbers without dispersion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | up to 5 days | The value of 89Zr-panitumumab and panitumumab-IRDye800 as a label for cancer cells (radiologic or fluorescent, respectively), was assessed by the sensitivity and specificity for the detection of tumor cells in lymph nodes near the tumor. 18F-fluorodeoxyglucose (18F-FDG), an established agent for this use, was also assessed. Sensitivity was assessed as the true positive rate of paired measurements, expressed as the proportion (ratio) of the number of specimens positive by histopathology also positive by the test method (test:histopathology). Specificity is the true negative rate, the proportion of the number of specimens negative by histopathology also negative by the test method. The closer the proportions are to 1, the greater the sensitivity or specificity. The outcome is reported as the sensitivity and specificity of 89Zr-panitumumab, panitumumab-IRDye800, and 18F-fluorodeoxyglucose (18F-FDG). The outcome results are ratios, a number without dispersion. |
Other
| Measure | Time frame | Description |
|---|---|---|
| 89Zr-panitumumab and 18F-FDG False-negatives | up to 5 days | The value of experimental 89Zr-panitumumab as a radiologic label was assessed as the number of lymph nodes (LNs) that have false-negative results. A false-negative result in this study is one that does not indicate that cancer is present in the lymph node, when histopathologic evaluation confirms the presence of cancer in the lymph nodes. The outcome is reported as the number of false-negative lymph nodes observed after systemic labeling with 89Zr-panitumumab and 18F-FDG, an established agent for this use. The outcome results are numbers without dispersion. |
| Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG | up to 5 days | The value of experimental 89Zr-panitumumab as a radiologic label was assessed by determining the positive predictive value (PPV) and the negative predictive value (NPV). PPV is a measure of extent that positive-labeled samples that were actually cancer, expressed as a proportion (ratio) of the number of positive-labeled samples vs samples positive by histopathology (positive label/positive histopathology). NPV is a measure of extent that negative-labeled samples (not positive) that were actually NOT cancer, expressed as a proportion (ratio) of the number of negative-labeled samples vs samples NOT positive by histopathology (negative label/negative histopathology). The closer the proportions are to 1, the better the predictive value. The outcome is reported as the PPV and NPV of 89Zr-panitumumab and 18F-fluorodeoxyglucose (18F-FDG), an established agent for this use. The outcome results are ratios, numbers without dispersion. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) Participants whose lymph nodes are negative for cancer
Panitumumab-IRDye800: 30 mg administered intravenously (IV)
Zirconium Zr-89 Panitumumab: 0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
Pinpoint IR IR9000 fluorescence-imaging system (FIS): Handheld fluorescence-imaging endoscope manufactured by Novadaq
SPY-PHI IR9000 fluorescence imaging system (FIS): Handheld fluorescence-imaging endoscope manufactured by Novadaq
Explorer Air camera: Fluorescence camera manufactured by SurgVision
PDE-NEO II camera: Medical infrared camera manufactured by Hamamatsu Photonics KK
FIS-00 fluorescence imaging system (FIS): Fluorescence-imaging system (FIS) manufactured by Hamamatsu Photonics KK
Da Vinci Firefly Imaging System: Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
IGP-ELVIS-v4 Macroscopic Specimen Imager: Macroscopic specimen imager manufactured by LI-COR Biosciences
Vevo 3100 LAZR-X: Photoacoustic ultrasound imaging system manufactured by VisualSonics
Pearl Triology Imaging System: Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
Odyssey CLx Imaging System: Infrared fluorescent imaging system manufactured by LI-COR Biosciences
Leica fluorescence microscope: Fluorescence microscope manufactured by Leica | 7 |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) Participants whose lymph nodes are positive for cancer.
Panitumumab-IRDye800: 30 mg administered intravenously (IV)
Zirconium Zr-89 Panitumumab: 0.8 to 1.2 mCi (29 to 45 Mbq) administered intravenously (IV)
Pinpoint IR IR9000 fluorescence-imaging system (FIS): Handheld fluorescence-imaging endoscope manufactured by Novadaq
SPY-PHI IR9000 fluorescence-imaging system (FIS): Handheld fluorescence-imaging endoscope manufactured by Novadaq
Explorer Air camera: Fluorescence camera manufactured by SurgVision
PDE-NEO II camera: Medical infrared camera manufactured by Hamamatsu Photonics KK
FIS-00 fluorescence imaging system (FIS): Fluorescenc3-imaging system (FIS) manufactured by Hamamatsu Photonics KK
Da Vinci Firefly Imaging System: Fluorescence-imaging endoscope, mounted or stand-alone, manufactured by Intuitive Surgical Inc
IGP-ELVIS-v4 Macroscopic Specimen Imager: Macroscopic specimen imager manufactured by LI-COR Biosciences
Vevo 3100 LAZR-X: Photoacoustic ultrasound imaging system manufactured by VisualSonics
Pearl Triology Imaging System: Near-infrared fluorescent and bioluminescent imaging system manufactured by LI-COR Biosciences
Odyssey CLx Imaging System: Infrared fluorescent imaging system manufactured by LI-COR Biosciences
Leica fluorescence microscope: Fluorescence microscope manufactured by Leica | 7 |
| Total | 14 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Lymph nodes not collected or not evaluable | 4 | 2 |
Baseline characteristics
| Characteristic | Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 3 Participants | 5 Participants | 8 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 2 Participants | 6 Participants |
| Age, Continuous | 63.8 years | 69.8 years | 68.3 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 6 Participants | 13 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 6 Participants | 6 Participants | 12 Participants |
| Region of Enrollment United States | 7 participants | 7 participants | 14 participants |
| Sex: Female, Male Female | 3 Participants | 1 Participants | 4 Participants |
| Sex: Female, Male Male | 4 Participants | 6 Participants | 10 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 7 | 0 / 7 |
| other Total, other adverse events | 7 / 7 | 7 / 7 |
| serious Total, serious adverse events | 1 / 7 | 0 / 7 |
Outcome results
Primary
Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling
The ability of 89Zr-panitumumab and 18F-fluorodeoxyglucose (18F-FDG) to detect tumor in lymph nodes were assessed on the basis of radiologic scans and histopathologic evaluation of excised lymph nodes (LNs). The histopathologic assessment was considered the definitive, regular medical care, assessment. The outcome is reported by study group as the number of LNs that were identified as tumor-positive by 18F-FDG- and 89Zr-panitumumab, stratified by the tumor-positivity as assessed by histopathology, and expressed as the number of LNs that were tumor-positive by both, negative for both, or positive for one and not the other. Results are also provided by study group for the number of LNs that tumor-positive by both 18F-FDG- and 89Zr-panitumumab, negative for both, or positive for one and not the other. The outcome is numbers without dispersion
Time frame: up to 5 days
Population: Some participants did not have lymph nodes collected, or the collected lymph nodes were not evaluable. Some lymph nodes were not evaluable by all methodologies.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-positive & pathology-positive | 0 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-positive & pathology-negative | 0 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-negative & pathology-positive | 0 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-negative & pathology-negative | 5 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 18F-FDG-positive & pathology-positive | 0 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 18F-FDG-positive & pathology-negative | 0 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 18F-FDG-negative & pathology-positive | 0 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 18F-FDG-negative & pathology-negative | 6 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-positive & 18F-FDG-positive | 0 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-positive & 18F-FDG-negative | 0 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-negative & 18F-FDG-positive | 0 Lymph Nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-negative & 18F-FDG-negative | 5 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-negative & 18F-FDG-positive | 8 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-positive & pathology-positive | 4 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 18F-FDG-negative & pathology-positive | 2 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-positive & pathology-negative | 0 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-positive & 18F-FDG-negative | 1 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-negative & pathology-positive | 6 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 18F-FDG-negative & pathology-negative | 6 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-negative & pathology-negative | 6 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-negative & 18F-FDG-negative | 4 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 18F-FDG-positive & pathology-positive | 7 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 89Zr-panitumumab-positive & 18F-FDG-positive | 2 Lymph Nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Detection of Tumor in Lymph Nodes by 18F-FDG and 89Zr-panitumumab Labeling | 18F-FDG-positive & pathology-negative | 3 Lymph Nodes |
Secondary
Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800
The value of 89Zr-panitumumab and panitumumab-IRDye800 as a label for cancer cells (radiologic or fluorescent, respectively), was assessed by the sensitivity and specificity for the detection of tumor cells in lymph nodes near the tumor. 18F-fluorodeoxyglucose (18F-FDG), an established agent for this use, was also assessed. Sensitivity was assessed as the true positive rate of paired measurements, expressed as the proportion (ratio) of the number of specimens positive by histopathology also positive by the test method (test:histopathology). Specificity is the true negative rate, the proportion of the number of specimens negative by histopathology also negative by the test method. The closer the proportions are to 1, the greater the sensitivity or specificity. The outcome is reported as the sensitivity and specificity of 89Zr-panitumumab, panitumumab-IRDye800, and 18F-fluorodeoxyglucose (18F-FDG). The outcome results are ratios, a number without dispersion.
Time frame: up to 5 days
Population: Some participants did not have lymph nodes collected, or the collected lymph nodes were not evaluable. Some lymph nodes were not evaluable by all methodologies.Some participants did not have lymph nodes collected, or the collected lymph nodes were not evaluable. Some lymph nodes were not evaluable by all methodologies.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | 89Zr-panitumumab Sensitivity | 0 Ratio |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | 89Zr-panitumumab Specificity | 0 Ratio |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | Panitumumab-IRDye800 Sensitivity | 0 Ratio |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | Panitumumab-IRDye800 Specificity Panitumumab-IRDye800 Specificity | 0 Ratio |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | 18F-FDG Sensitivity | 0 Ratio |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | 18F-FDG Specificity | 0 Ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | 18F-FDG Sensitivity | 0.78 Ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | 89Zr-panitumumab Sensitivity | 0.4 Ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | Panitumumab-IRDye800 Specificity Panitumumab-IRDye800 Specificity | 1.0 Ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | 89Zr-panitumumab Specificity | 1.0 Ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | 18F-FDG Specificity | 0.67 Ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Sensitivity and Specificity of 89Zr-panitumumab, 18F-FDG, and Panitumumab-IRDye800 | Panitumumab-IRDye800 Sensitivity | 1.0 Ratio |
Other Pre-specified
89Zr-panitumumab and 18F-FDG False-negatives
The value of experimental 89Zr-panitumumab as a radiologic label was assessed as the number of lymph nodes (LNs) that have false-negative results. A false-negative result in this study is one that does not indicate that cancer is present in the lymph node, when histopathologic evaluation confirms the presence of cancer in the lymph nodes. The outcome is reported as the number of false-negative lymph nodes observed after systemic labeling with 89Zr-panitumumab and 18F-FDG, an established agent for this use. The outcome results are numbers without dispersion.
Time frame: up to 5 days
Population: Some participants did not have lymph nodes collected, or the collected lymph nodes were not evaluable. Some lymph nodes were not evaluable by all methodologies.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | 89Zr-panitumumab and 18F-FDG False-negatives | 89Zr-panitumumab False-negatives | 0 Lymph nodes |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | 89Zr-panitumumab and 18F-FDG False-negatives | 18F-FDG False-negatives | 0 Lymph nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | 89Zr-panitumumab and 18F-FDG False-negatives | 89Zr-panitumumab False-negatives | 6 Lymph nodes |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | 89Zr-panitumumab and 18F-FDG False-negatives | 18F-FDG False-negatives | 2 Lymph nodes |
Other Pre-specified
Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG
The value of experimental 89Zr-panitumumab as a radiologic label was assessed by determining the positive predictive value (PPV) and the negative predictive value (NPV). PPV is a measure of extent that positive-labeled samples that were actually cancer, expressed as a proportion (ratio) of the number of positive-labeled samples vs samples positive by histopathology (positive label/positive histopathology). NPV is a measure of extent that negative-labeled samples (not positive) that were actually NOT cancer, expressed as a proportion (ratio) of the number of negative-labeled samples vs samples NOT positive by histopathology (negative label/negative histopathology). The closer the proportions are to 1, the better the predictive value. The outcome is reported as the PPV and NPV of 89Zr-panitumumab and 18F-fluorodeoxyglucose (18F-FDG), an established agent for this use. The outcome results are ratios, numbers without dispersion.
Time frame: up to 5 days
Population: Some participants did not have lymph nodes collected, or the collected lymph nodes were not evaluable. Some lymph nodes were not evaluable by all methodologies.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG | 89Zr-panitumumab Positive Predictive Value (PPV) | 0 ratio |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG | 89Zr-panitumumab Negative Predictive Value (NPV) | 0 ratio |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG | 18F-FDG Positive Predictive Value (PPV) | 0 ratio |
| Tumor-negative Lymph Nodes (by 18F-FDG Scan) | Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG | 18F-FDG Negative Predictive Value (NPV) | 0 ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG | 18F-FDG Negative Predictive Value (NPV) | 0.67 ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG | 89Zr-panitumumab Positive Predictive Value (PPV) | 0.4 ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG | 18F-FDG Positive Predictive Value (PPV) | 0.78 ratio |
| Tumor-positive Lymph Nodes (by 18F-FDG Scan) | Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of 89Zr-panitumumab and 18F-FDG | 89Zr-panitumumab Negative Predictive Value (NPV) | 1.0 ratio |